Is Nidan Laborator. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be significantly overvalued compared to its peers.
In comparison to its industry peers, Nidan Laborator. has a lower PE ratio than Apollo Hospitals, which stands at 65.65, and a more favorable EV to EBITDA ratio compared to Max Healthcare at 56.83. However, the company's return metrics, such as a ROCE of 3.44% and ROE of 2.90%, highlight its struggles in generating returns relative to its equity. Additionally, Nidan Laborator. has underperformed against the Sensex over the past year, with a stock return of -34.69% compared to the Sensex's 5.34%, reinforcing the notion that the company is currently fairly valued in a challenging market environment.